Pricing Log in Create free account

Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs Novogen Limited (KZIA)

Corbus Pharmaceuticals Holdings, Inc. and Novogen Limited are both Biotechnology companies. Corbus Pharmaceuticals Holdings, Inc. and Novogen Limited are of similar size ($84.6M and $83.8M). Across the 10 metrics below, Novogen Limited leads on 7 and Corbus Pharmaceuticals Holdings, Inc. on 3.

Valuation

Metric CRBP KZIA Biotechnology median
P/E n/m n/m 8.50
P/S 56.97 n/m 9.71
P/B 0.86 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.07 1.46 0.64
EV/Sales (5.25) n/m 9.21
Earnings yield (136.95%) (2.98%) (33.15%)
Free cash flow yield (98.82%) 0.00% (25.50%)

Profitability

Metric CRBP KZIA Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (95.58%) 0.00% (56.36%)
Return on assets (80.85%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBP KZIA Biotechnology median
Revenue growth (TTM) (73.69%) — 6.02%
EPS growth (last fiscal year) (60.33%) 63.24% 30.26%
Revenue growth, 5-year CAGR (14.34%) 11.56% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBP KZIA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.71 2.87 4.72
Net debt to EBITDA 1.90 0.30 0.96

Dividend

Metric CRBP KZIA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRBP KZIA Biotechnology median
Market cap 83.75m 84.58m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack